Premium
Tricuspid valve endocarditis in the era of the opioid epidemic
Author(s) -
Wallen Tyler J.,
Szeto Wilson,
Williams Matthew,
Atluri Pavan,
Arnaoutakis George,
Fults Marci,
Sultan Ibrahim,
Desai Nimesh,
Acker Michael,
Vallabhajosyula Prashanth
Publication year - 2018
Publication title -
journal of cardiac surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 58
eISSN - 1540-8191
pISSN - 0886-0440
DOI - 10.1111/jocs.13600
Subject(s) - medicine , endocarditis , tricuspid valve , incidence (geometry) , surgery , stroke (engine) , dialysis , infective endocarditis , cardiology , mechanical engineering , physics , optics , engineering
Abstract Background and Aim We reviewed our institutional experience with tricuspid valve endocarditis to understand the impact of the opioid epidemic on the incidence of right heart endocarditis. Methods We retrospectively reviewed all cases of tricuspid endocarditis managed surgically from January of 2011 to May of 2017. There were no exclusion criteria. Results A total of 126 patients were identified. There were seven cases in 2011 and 36 in 2016. The average age of the patients decreased from 52.85 ± 19.6 years in 2011 to 39.2 ± 12.9 in 2017. Caucasians comprised 71% of the patients in 2011 and 75% in 2016. Tricuspid valve replacement was performed in 74 patients (58.73%) and repair was performed in 52 (41.27%). Thirty‐day mortality was 11.11%. Reoperation, stroke and renal failure requiring dialysis during the index hospitalization were 5.6%, 0.8%, and 8%, respectively. Staphylococcus aureus , found in 43% of cases, was the most common isolate throughout the study period. Streptococcus was the second most common causative agent. Conclusions In a span of 5 years, our institution has noted a fivefold increase in surgical volume for tricuspid endocarditis, most likely related to the impact of the opioid epidemic.